Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis

Published:2024-06-26 Issue:2 Volume:28 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Yu Jiahui¹,Yan Duan²,Wei Song²,Yang Linfeng²,Yi Pengsheng²

Affiliation:

1. Department of Hepato‑Biliary‑Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China

2. Department of Hepato‑Biliary‑Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China

Publisher

Spandidos Publications

Reference64 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline;Gordan;J Clin Oncol,2020

3. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations;Nault;J Hepatol,2018

4. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update;Reig;J Hepatol,2022

5. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma;Cabibbo;Hepatology,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP